Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the EU on 6th January 2021. The patent number is EP3341754. This reinforces the first patent grant which was in the USA back in January 2020. The company has further patents pending in key large countries which have high numbers of radiotherapy cancer treatment centres.
on PATENTSCOP
on Espacenet
Related Posts
This order is for a number of DOSEmapper™ devices and for our DOSEmapper™ Bead Reading Service.
Graduate secures vital government backing for innovative cancer treatment, targeting global markets with Sirius Programme.
TRUEinvivo joined SyndicateRoom investment platform in February 2019, leveraging its network to connect with potential investors, alongside Nexus Investment Ventures Ltd,
TrueInvivo's implant improves cancer treatment accuracy, accessible globally, supported by UKTI Sirius Programme.
